Jueves, 23 Marcha, 2017

Analysts Upgrade/Downgrade Activity of Endo International plc (ENDP)

Cris De Lacerda | 21 Marcha, 2017, 02:58

Endo International plc - has a 12-month low of $9.82 and a 12-month high of $35.34. Oppenheimer Holdings Inc. reissued a hold rating on shares of Endo International plc - in a report on Wednesday, March 1st. The shares opened for trading at $10.63 and hit $10.94 on the upside, eventually ending the session at $10.82, with a gain of 2.75% or 0.29 points. The price targets are usually acts as the boosters or blasters in the performance of stock. There may be various price targets for a stock. Covering analysts use their acquired knowledge and expertise to help create their best calculation of where they think the stock may be moving in the future. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Moreover, JP Morgan issued Downgrade rating for the stock on 20-Jan-17. Company price to earnings (P/E) ratio, which measures the relationship between the earnings of a company and its stock price, is calculated as 26.45. The company rocked its 52-Week High of $35.34 on April 22, 2016 and touched its 52-Week Low of $9.82 on Mar 15, 2017. Analyst's mean target price for ENDP is $17.50 while analysts mean recommendation is 2.50. According to these analysts, the Low Revenue Estimate for Endo International plc is 964.57 Million and the High Revenue Estimate is 1.08 Billion.

Endo International plc (NASDAQ: ENDP) declared that the U.S. Food and Drug Administration's (FDA) Drug Safety Risk Administration and Anesthetic and Analgesic Drug Products Advisory Committees voted 18 to eight, with one abstention, that the benefits of reformulated OPANA ER no longer outweigh its risks. The stock is up 43.57% in this year through last close, and the beta ratio has a value of 2.29.

Taking a brief view of stock performance, we see that Endo International plc (NASDAQ:ENDP) shares are now trading $-1.512 off the 50-day moving average of $12.137 and $-5.766 off of the 200-day moving average of $16.391. The analysts offering Earnings Estimates for the company were believing that Endo International plc (ENDP) could bring EPS of $1.63/share. Higher EPS estimate is noted at $1.00 while lowest EPS estimate among analysts is targeted at $0.67. The company's market cap is $2.4 Billion. The company's last traded volume of 12.6 million shares as compared to it's an average volume of 8.65 million shares.

During last 5 trades the stock sticks nearly -6.24%. Finally, Barclays PLC decreased their target price on Endo International plc - from $22.00 to $15.00 and set an equal weight rating on the stock in a report on Monday, February 6th. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of -10.27%. The stock is now has its Return on Assets (ROA) value of -19.5 Percent. Presently, it has a Return on Equity (ROE) of -63.90% and Return on Investment (ROI) of -25.30%.

The Stock has Weekly volatility of 5.20% and monthly volatility of 5.61%. The business's revenue was up 15.6% compared to the same quarter past year. Finally, Mitsubishi UFJ Trust & Banking Corp raised its position in shares of Endo International plc - by 1.1% in the third quarter. According to their predictions High & Low revenue estimates are 1.08 Billion and 964.57 Million respectively. There was a stock increase by 1.14 percent. Adjusted net loss for the fourth quarter of 2016 was $27.9 million, or $0.57 per diluted share, compared to adjusted net loss of $8.4 million, or $0.17 per diluted share for the fourth quarter of 2015.